Trial designs used to study neuroprotective therapy in Parkinson's disease
Identifieur interne : 000947 ( Istex/Curation ); précédent : 000946; suivant : 000948Trial designs used to study neuroprotective therapy in Parkinson's disease
Auteurs : Anthony E. Lang [Canada] ; Eldad Melamed [Israël] ; Werner Poewe [Autriche] ; Olivier Rascol [France]Source :
- Movement Disorders [ 0885-3185 ] ; 2013-01.
Abstract
There have been numerous trials conducted to evaluate putative disease‐modifying or neuroprotective treatments in Parkinson's disease. These trials have used several different study designs and outcome measures. Each of these has its own strengths and weaknesses. Confounding all studies is the potential symptomatic benefit that the treatment might have on the features of Parkinson's disease. In addition, patient‐related factors such as age of onset and the nature of the dominant symptoms may have important impacts that are often not addressed. Here we provide an overview of the various trial designs that have been used and emphasize the challenges faced in attempting to study neuroprotection in Parkinson's disease and the advances needed before this goal can be successfully achieved. © 2013 Movement Disorder Society
Url:
DOI: 10.1002/mds.24997
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000947
Links to Exploration step
ISTEX:1F8441423F9E5A20B3681C5AA731F29E6D85371FLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Trial designs used to study neuroprotective therapy in Parkinson's disease</title><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation wicri:level="1"><mods:affiliation>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J Safra Program in Parkinson's Disease, Toronto Western Hospital, Ontario, Toronto, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J Safra Program in Parkinson's Disease, Toronto Western Hospital, Ontario, Toronto</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>E-mail: lang@uhnres.utoronto.ca</mods:affiliation><country wicri:rule="url">Canada</country></affiliation></author><author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name><affiliation wicri:level="1"><mods:affiliation>The Norma and Alan Aufzien Chair for Resarch of Parkinson's Disease, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel</mods:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>The Norma and Alan Aufzien Chair for Resarch of Parkinson's Disease, Sackler School of Medicine, Tel Aviv University, Tel Aviv</wicri:regionArea></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, Innsbruck Medical University, Innsbruck</wicri:regionArea></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><mods:affiliation>Clinical Investigation Center and Department of Clinical Pharmacology and Neurosciences, CIC9302 INSERM and UMR825, Toulouse University Hospital, University of Toulouse‐3, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Clinical Investigation Center and Department of Clinical Pharmacology and Neurosciences, CIC9302 INSERM and UMR825, Toulouse University Hospital, University of Toulouse‐3, Toulouse</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1F8441423F9E5A20B3681C5AA731F29E6D85371F</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1002/mds.24997</idno><idno type="url">https://api-v5.istex.fr/document/1F8441423F9E5A20B3681C5AA731F29E6D85371F/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000947</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000947</idno><idno type="wicri:Area/Istex/Curation">000947</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Trial designs used to study neuroprotective therapy in Parkinson's disease</title><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation wicri:level="1"><mods:affiliation>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J Safra Program in Parkinson's Disease, Toronto Western Hospital, Ontario, Toronto, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J Safra Program in Parkinson's Disease, Toronto Western Hospital, Ontario, Toronto</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>E-mail: lang@uhnres.utoronto.ca</mods:affiliation><country wicri:rule="url">Canada</country></affiliation></author><author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name><affiliation wicri:level="1"><mods:affiliation>The Norma and Alan Aufzien Chair for Resarch of Parkinson's Disease, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel</mods:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>The Norma and Alan Aufzien Chair for Resarch of Parkinson's Disease, Sackler School of Medicine, Tel Aviv University, Tel Aviv</wicri:regionArea></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, Innsbruck Medical University, Innsbruck</wicri:regionArea></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><mods:affiliation>Clinical Investigation Center and Department of Clinical Pharmacology and Neurosciences, CIC9302 INSERM and UMR825, Toulouse University Hospital, University of Toulouse‐3, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Clinical Investigation Center and Department of Clinical Pharmacology and Neurosciences, CIC9302 INSERM and UMR825, Toulouse University Hospital, University of Toulouse‐3, Toulouse</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov Disord</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><date type="published" when="2013-01">2013-01</date><biblScope unit="volume">28</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="86">86</biblScope><biblScope unit="page" to="95">95</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">1F8441423F9E5A20B3681C5AA731F29E6D85371F</idno><idno type="DOI">10.1002/mds.24997</idno><idno type="ArticleID">MDS24997</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">There have been numerous trials conducted to evaluate putative disease‐modifying or neuroprotective treatments in Parkinson's disease. These trials have used several different study designs and outcome measures. Each of these has its own strengths and weaknesses. Confounding all studies is the potential symptomatic benefit that the treatment might have on the features of Parkinson's disease. In addition, patient‐related factors such as age of onset and the nature of the dominant symptoms may have important impacts that are often not addressed. Here we provide an overview of the various trial designs that have been used and emphasize the challenges faced in attempting to study neuroprotection in Parkinson's disease and the advances needed before this goal can be successfully achieved. © 2013 Movement Disorder Society</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000947 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000947 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:1F8441423F9E5A20B3681C5AA731F29E6D85371F
|texte= Trial designs used to study neuroprotective therapy in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.29. |  |